SCHEMBL19781550

SCHEMBL19781550

CC(C)Oc1ccc(-c2ccc3cncn3c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.40
PTPN5 P54829 1/20 0.38
WDR5 P61964 1/20 0.38
ALDH1A3 P47895 2/20 0.38
MAP4K4 O95819 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
CYP1A2 P05177 1/20 0.37
BTK Q06187 1/20 0.36
MCL1 Q07820 1/20 0.36
NOTUM Q6P988 1/20 0.35
BMPR1B O00238 1/20 0.35
ACVR1B P36896 1/20 0.35
ACVRL1 P37023 1/20 0.35
ACVR1 Q04771 1/20 0.35
QPCT Q16769 1/20 0.35
QPCTL Q9NXS2 1/20 0.35
BRD4 O60885 1/20 0.34
CREBBP Q92793 1/20 0.34
CLK1 P49759 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21965732 0.87 ALDH1A3 (0.38) WDR5ALDH1A3TP53MAPTCYP1A2
SCHEMBL29303795 0.80 EGLN1 (0.39) PTPN5TP53NOTUMBRD4CREBBP
SCHEMBL19781274 0.75 SCN5A (0.44) FDPSPTPN5WDR5MAP4K4TP53
SCHEMBL19781793 0.73 SCN5A (0.61) FDPSPTPN5WDR5ALDH1A3MAP4K4
SCHEMBL197284 0.72 ALDH1A3 (0.56) PTPN5ALDH1A3MAP4K4CYP1A2MCL1
SCHEMBL13931947 0.72 QPCT (0.44) ALDH1A3MAPTCYP1A2QPCTQPCTL
SCHEMBL19781584 0.72 KDM4E (0.47) FDPSPTPN5WDR5MAP4K4TP53
SCHEMBL19781273 0.71 SCN5A (0.43) FDPSPTPN5WDR5MAP4K4TP53
SCHEMBL24460393 0.70 DYRK1A (0.59) FDPSWDR5ALDH1A3CYP1A2
SCHEMBL16589292 0.68 TBXAS1 (0.39) NOTUMBRD4CREBBPTBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2022-09-08 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION C9, C1S, ZC3HAV1 FDPS 2125/4885PTPN5 4181/4885WDR5 3258/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S FDPS 1958/4885PTPN5 4347/4885WDR5 3465/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S FDPS 1958/4885PTPN5 4347/4885WDR5 3465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.